Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01182493 · ClinicalTrials.gov registry record · NA
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
A NA study of Diabetes Mellitus, Type 2, sponsored by Medtronic Diabetes.
- Completed
- Registry status
- NA
- Development phase
- 331
- Enrollment target
- 20
- Study locations
NCT01182493 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by Medtronic Diabetes. The registered enrollment target is 331 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT01182493, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by Medtronic Diabetes.
- COMPLETED
- Registry status
- NA
- Development phase
- 331 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).
Conditions Studied
Interventions
- DEVICE Insulin Pump (Medtronic Minimed Paradigm® VEO)
Study Locations (20)
Other
- City hopital Vienna-Hieting - Vienna
- CHU Côte de Nacre - Caen
- CHU - Ste Marguerite - Marseille
- Hopital Lapeyronie - Montpellier
- CHU de Nancy - Nancy
- CHU Strasbourg - Strasbourg
- CHU Toulouse Rangueil - Toulouse
- Fachklinik Bad Heilbrunn - Bad Heilbrunn
- Zentrum für Diabetes und Gefäßerkrankungen - Münster
Ontario
- LMC Endocrinology Centre - Oakville
- Canadian Centre for Research on Diabetes - Smiths Falls
- Toronto General Hsopital - Toronto
New York
- Albany Medical College - Albany
- SUNY Upstate Medical University - Syracuse
British Columbia
- Endocrinologist, 202-301 Columbia Street East - New Westminster
- 416-1033 Davie St - Vancouver
Georgia
- Atlanta Diabetes Associates - Atlanta
Alberta
- Clinical Professor Department of Medicine University of Calgary - Calgary
Newfoundland and Labrador
- Health Science Centre - St. John's
Quebec
- McGill University, McGill Nutrition and Food Science Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01182493
The ClinicalTrials.gov registry entry for NCT01182493 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (93% lower). The listed sponsor is Medtronic Diabetes, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Insulin Pump (Medtronic Minimed Paradigm® VEO) is the first listed.
NCT01182493 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Ontario, New York.
Frequently Asked Questions
What is clinical trial NCT01182493 about?
NCT01182493 is a clinical study titled "OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy". The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).
What is the current status of trial NCT01182493?
This trial is currently completed. It is a NA study. The enrollment target is 331 participants. The study started on 2010-12. Estimated completion is 2014-08.
What conditions does trial NCT01182493 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01182493?
The interventions under investigation include: Insulin Pump (Medtronic Minimed Paradigm® VEO) (DEVICE).
Who is sponsoring clinical trial NCT01182493?
This trial is sponsored by Medtronic Diabetes, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01182493 being conducted?
This trial has 20 study locations across Georgia, New York, Alberta, British Columbia, Newfoundland and Labrador. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.